Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
TECHNOLOGY
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
LATEST NEWS
TECHNOLOGY
Excited? Don't Be. It's Reverse-Split Time
By George Mannes
Jun 18, 2001 6:49 PM EDT
PRESS RELEASES
Mirum Pharmaceuticals Honors Alagille Syndrome Awareness Day With Launch Of Disease Awareness Campaign
By Business Wire
Jan 24, 2021 9:00 AM EST
PRESS RELEASES
Mirum Pharmaceuticals Announces First Patient Enrolled In Phase 2b VISTAS Clinical Study Evaluating Volixibat In Adult Patients With Primary Sclerosing Cholangitis
By Business Wire
Jan 14, 2021 9:00 AM EST
PRESS RELEASES
Mirum Pharmaceuticals Provides Corporate Update
By Business Wire
Jan 12, 2021 9:00 AM EST
PRESS RELEASES
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By Business Wire
Jan 8, 2021 6:17 PM EST
PRESS RELEASES
Mirum Pharmaceuticals To Present At The 39th Annual J.P. Morgan Healthcare Conference On January 12, 2021
By Business Wire
Jan 4, 2021 8:30 AM EST
PRESS RELEASES
Mirum Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
By Business Wire
Dec 14, 2020 9:00 PM EST
PRESS RELEASES
Mirum Pharmaceuticals Announces Commencement Of Public Offering Of Common Stock
By Business Wire
Dec 14, 2020 7:00 AM EST
PRESS RELEASES
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By Business Wire
Dec 10, 2020 7:41 PM EST
PRESS RELEASES
Mirum Pharmaceuticals And Oberland Capital Announce Up To $210 Million Funding Arrangement
By Business Wire
Dec 9, 2020 9:00 AM EST
PRESS RELEASES
Mirum Pharmaceuticals Announces European Medicines Agency Validation Of The Marketing Authorization Application For Maralixibat In Patients With PFIC2
By Business Wire
Nov 30, 2020 8:30 AM EST
PRESS RELEASES
Mirum Pharmaceuticals To Present At Upcoming Investor Conferences
By Business Wire
Nov 23, 2020 9:30 AM EST
PRESS RELEASES
Mirum Pharmaceuticals Announces Data Presented During AASLD Highlighting Durable Improvements In Pruritus And Quality Of Life In Children With Alagille Syndrome Treated With Maralixibat
By Business Wire
Nov 15, 2020 6:00 PM EST
PRESS RELEASES
Mirum Pharmaceuticals Presents New Data From Its Maralixibat And Volixibat Clinical Studies At AASLD Annual Meeting
By Business Wire
Nov 13, 2020 8:10 AM EST
PRESS RELEASES
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By Business Wire
Nov 10, 2020 7:00 PM EST
PRESS RELEASES
Mirum Pharmaceuticals Broadens Expanded Access Program For Maralixibat In Alagille Syndrome To Europe And Australia
By Business Wire
Nov 5, 2020 8:30 AM EST
PRESS RELEASES
Mirum Pharmaceuticals Announces New Data Being Presented In Late-Breaker Oral And Poster Presentations At The Annual Meeting Of The American Association For The Study Of Liver Diseases (AASLD)
By Business Wire
Nov 2, 2020 8:30 AM EST
PRESS RELEASES
Mirum Pharmaceuticals To Present Maralixibat Data And Host Symposium At The NASPGHAN Annual Meeting 2020
By Business Wire
Oct 26, 2020 8:30 AM EDT
PRESS RELEASES
Mirum Pharmaceuticals Announces Partnership With EVERSANA To Support Launch And Commercialization Of Maralixibat For Alagille Syndrome In The United States
By PR Newswire
Oct 15, 2020 8:55 AM EDT
PRESS RELEASES
Mirum Pharmaceuticals Announces Partnership With EVERSANA To Support Launch And Commercialization Of Maralixibat For Alagille Syndrome In The United States
By Business Wire
Oct 15, 2020 8:45 AM EDT
PRESS RELEASES
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By Business Wire
Oct 13, 2020 4:05 PM EDT
PRESS RELEASES
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By Business Wire
Sep 11, 2020 4:30 PM EDT
PRESS RELEASES
Mirum Pharmaceuticals To Present At Investor Conferences In September
By Business Wire
Sep 11, 2020 7:00 AM EDT
PRESS RELEASES
(Graphic: Business Wire)
By Business Wire
Aug 29, 2020 8:45 AM EDT
PRESS RELEASES
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
By Business Wire
Aug 11, 2020 5:30 PM EDT